tetano
Editor, Senior Moderator
Sci Rep
. 2023 Jul 8;13(1):11071.
doi: 10.1038/s41598-023-35505-w. Cellular immunity reflects the persistent symptoms among COVID-19 recovered patients in Japan
Yoshiharu Miyata[SUP] #[/SUP][SUP] 1 [/SUP], Kohjin Suzuki[SUP] #[/SUP][SUP] 2 [/SUP], Tatsuya Nagano[SUP] #[/SUP][SUP] 3 [/SUP], Keiji Iida[SUP] 4 [/SUP], Takehiro Hasegawa[SUP] 5 [/SUP], Hitoshi Uga[SUP] 6 [/SUP], Hiroshi Matsuoka[SUP] 7 [/SUP]
Affiliations
Coronavirus disease (COVID-19) often causes persistent symptoms long after infection, referred to as "long COVID" or post-acute COVID-19 syndrome (PACS). This phenomenon has been studied primarily concerning B-cell immunity, while the involvement of T-cell immunity is still unclear. This retrospective study aimed to examine the relationship among the number of symptoms, cytokine levels, and the Enzyme-linked immunosorbent spot (ELISPOT) assay data in patients with COVID-19. To examine inflammatory conditions, plasma interleukin (IL)-6, IL-10, IL-18, chemokine ligand 9 (CXCL9), chemokine ligand 3 (CCL3), and vascular endothelial growth factor (VEGF) levels were analyzed using plasma obtained from COVID-19 recovery patients and healthy controls (HC). These levels were significantly higher in the COVID-19 group than those in the HC group. ELISPOT assays were performed to investigate the correlation between COVID-19 persistent symptoms and T-cell immunity. Cluster analysis of ELISPOT categorized COVID-19 recovery patients in the ELISPOT-high and -low groups, based on the values of S1, S2, and N. The number of persistent symptoms was significantly higher in the ELISPOT-low group than those in the ELISPOT-high group. Thus, T cell immunity is critical for the rapid elimination of COVID-19 persistent symptoms, and its measurement immediately after COVID-19 recovery might predict long-term COVID-19 or PACS.
. 2023 Jul 8;13(1):11071.
doi: 10.1038/s41598-023-35505-w. Cellular immunity reflects the persistent symptoms among COVID-19 recovered patients in Japan
Yoshiharu Miyata[SUP] #[/SUP][SUP] 1 [/SUP], Kohjin Suzuki[SUP] #[/SUP][SUP] 2 [/SUP], Tatsuya Nagano[SUP] #[/SUP][SUP] 3 [/SUP], Keiji Iida[SUP] 4 [/SUP], Takehiro Hasegawa[SUP] 5 [/SUP], Hitoshi Uga[SUP] 6 [/SUP], Hiroshi Matsuoka[SUP] 7 [/SUP]
Affiliations
- PMID: 37422499
- PMCID: PMC10329673
- DOI: 10.1038/s41598-023-35505-w
Coronavirus disease (COVID-19) often causes persistent symptoms long after infection, referred to as "long COVID" or post-acute COVID-19 syndrome (PACS). This phenomenon has been studied primarily concerning B-cell immunity, while the involvement of T-cell immunity is still unclear. This retrospective study aimed to examine the relationship among the number of symptoms, cytokine levels, and the Enzyme-linked immunosorbent spot (ELISPOT) assay data in patients with COVID-19. To examine inflammatory conditions, plasma interleukin (IL)-6, IL-10, IL-18, chemokine ligand 9 (CXCL9), chemokine ligand 3 (CCL3), and vascular endothelial growth factor (VEGF) levels were analyzed using plasma obtained from COVID-19 recovery patients and healthy controls (HC). These levels were significantly higher in the COVID-19 group than those in the HC group. ELISPOT assays were performed to investigate the correlation between COVID-19 persistent symptoms and T-cell immunity. Cluster analysis of ELISPOT categorized COVID-19 recovery patients in the ELISPOT-high and -low groups, based on the values of S1, S2, and N. The number of persistent symptoms was significantly higher in the ELISPOT-low group than those in the ELISPOT-high group. Thus, T cell immunity is critical for the rapid elimination of COVID-19 persistent symptoms, and its measurement immediately after COVID-19 recovery might predict long-term COVID-19 or PACS.